This presents a valuable opportunity for ingredient companies to contribute significantly to the evolving landscape of weight management and health enhancement by integrating nutraceuticals into more packaged goods
However, tirzepatide has the significant advantage of FDA approval, which opens the door to insurance coverage
Retatrutide is a once-weekly injection that mimics three hormones involved in appetite, blood sugar, and how the body uses energy: GLP-1: lowers appetite and blood sugar GIP: lowers appetite and blood sugar Glucagon: increases energy expenditure and the breakdown of stored fat, including fat in the liver The glucagon component is what separates retatrutide from semaglutide, which mimics one hormone (GLP-1), and tirzepatide, which mimics two (GLP-1 and GIP)
GLP-1 receptor agonists were initially developed to improve glycemic control in type 2 diabetes by enhancing insulin secretion and inhibiting glucagon release, with additional effects on appetite regulation and gastric emptying later recognized as clinically relevant (Meloni et al
Still, clinical decisions depend on approval status, product labeling, side effects, diabetes treatment goals, cardiovascular risk, comorbid conditions, and patient preferences
The continuous in-depth research on the effects of GLP-1RAs on the occurrence and development of cancer in recent years have highlighted the increased potential for their use in the clinical treatment of cancer
.jpg)
